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ABSTRACT 
 
Objective: Pharmaceutical companies spend significant amount of resources on promotion influencing the 
prescribing behaviour of physicians. Drug promotion can negatively impact on rational prescribing, which 
may adversley affect the quality of patient care. However, little is know about these activities in Nigeria as 
the most populous country in Africa. We therefore aimed  to explore the nature of encounters between 
Nigerian physicians and pharmaceutical sales representatives (PSRs) and how these encounters 
influence prescribing habits. Methodology: Cross-sectional questionnaire-based study conducted among 
practicing physicians working in tertiary hospitals in four regions of Nigeria. Results: 176 questionnaires 
were completed. 154 respondents (87.5%) had medicines promoted to them in the previous three 
months, ZLWKPRVWHQFRXQWHUVWDNLQJSODFHLQRXWSDWLHQWV¶FOLQLFVclinical meetings (46%) and 
new medicine launches (17.6%). Information about potential adverse effects and drug interactions was 
provided in 41.5%, and 27.3% of cases, respectively. Food, in the form of lunch or dinner, was the most 
common form of incentive (70.5%) given to physicians during promotional activities. 61% of physicians 
felt motivated to prescribe the drug promoted to them, with quality of information provided being the 
driving factor. Most physicians (64.8%) would agree to some form of regulation of this relationship 
between medical doctors and the pharmaceutical industry. Conclusion: Interaction between PSRs and 
physicians is a regular occurrence in Nigeria, influencing prescribing practices. Meals and cheap gifts 
were the most common items offered to physicians during their encounters with PSRs. The need for 
some form of regulation by professional organizations and the government was expressed by most 
respondents to address current concerns.  
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1. INTRODUCTION 
 
In 2015, the pharmaceutical industry spent an estimated USD 69.2 billion on various forms of 
pharmaceutical promotion and advertising in 31 countries, 3.2% up from 20141. Most of this spending was 
on detailing (61.2%), followed by providing drug samples (10.8%), meetings (10.5%), direct-to-consumer 
advertising (8%), digital (3.8%), mailing/others (3.1%), clinical trials (2.1%) and other forms advertising 
(0.5%).  
 
7KH:RUOG+HDOWK2UJDQL]DWLRQGHILQHVSKDUPDFHXWLFDOSURPRWLRQDV³DOOLQIRUPDWLRQDODQGSHUVXDVLYH
activities by manufacturers, the effect of which is to induce the prescription, supply, purchase and/or use 
RIPHGLFLQDOGUXJV´2. Typically, product detailing by pharmaceutical sales representatives (PSRs) is via 
hospital or clinic visits, drug launches, visits to conferences and through continuing medical education 
programmes2-4. During their visits, PSRs can offer gifts, invitations to luncheons/dinners and free 
samples5. Pharmaceutical companies also sponsor meetings and conferences, offer research grants and 
honorarium to physicians, and sponsor clinical trials3,4,6,7. However, there are increasing concerns among 
patients regarding such activities8 due to their impact on prescribing and consumption of medicines.  
 
Pharmaceutical promotion and other marketing activities can influence both prescribers9-13 and users of 
promoted medicines,  potentially negatively impacting on medicine utilization patterns11,14,15. In addition, 
potentially adding to costs; for example, the total costs of proton pump inhibitors in Ireland when adjusted 
for population size with limited counter actions to pharmaceutical company activities versus Sweden with 
extensive health authority activities promoting generics first line when available16. Spurling et al in their 
review found that in studies examining prescribing quality, five studies found an association between 
exposure to pharmaceutical company information and lower quality prescribing whilst four did not, and 
one study found associations with both lower and higher quality prescribing. 38 studies found 
associations between exposure to companies and a higher frequency of prescribing whilst 13 did not. 
Five studies also found evidence of higher costs following company interactions, whilst four studies found 
no association and one study found an association with lower costs15. Vancelik et al also found that 
pharmaceutical companies were highly influential in prescribing by ambulatory care physicians in 
Turkey17; similarly, Akande et al in Nigeria18.  There are also concerns that information, especially around 
the risks and side-effects of medicines, are often missing from pharmaceutical company presentations, 
especially where they are the principle source of information as seen in a number of lower and middle 
income countries (LMICs)18-20. There are also concerns if only favourable findings are published and 
promoted by pharmaceutical companies21,22, especially with less than 70% of studies undertaken actually 
published23. In addition, as mentioned, there are concerns with physician trust if patients believe 
physicians have been unduly influenced by pharmaceutical companies with gift relationships8,24. 
 
Consequently, we believe it is important to regulate the interaction between the pharmaceutical industry, 
health providers and patients, especially where there are currently limited regulations and limited 
continuous professional development post qualification, coupled with high co-payments, as seen in many 
LMICs including Nigeria25,26. Whilst most developed countries have  national legislation regulating drug 
promotion involving  voluntary codes among professional organisations, including those working in key 
positions in the industry27,28, most of the day-to-day regulation  is turned over to pharmaceutical 
companies which have their own  codes of practice27-29.  
 
In Nigeria, the National Agency for Food and Drug Administration and Control (NAFDAC) has the 
mandate to regulate and control the advertisement of medicines30. However, it is unknown if any code of 
practice or guidelines are in place to address the promotion of prescription drugs promotion or direct to 
consumer advertisement in Nigeria. The Pharmaceutical Manufacturers Group of Manufacturers 
Association of Nigeria (PMG-MAN) is the umbrella of the Organization for Manufacturer of 
Pharmaceuticals and Allied Products in Nigeria, and currently PMG-MAN has no code for the marketing 
of prescription drugs. This is a concern as Nigeria is the most populous country in Africa with an 
estimated population of 185.9 million in 201631, with currently appreciable population growth. As a result, 
an appreciable opportunity to waste considerable resources for both the government and patients with 
inappropriate use of medicines.  
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We did not find any information on spending on pharmaceutical promotion in Africa, or the number of 
PSRs, in our review of the literature and the internet. However, we found an increased number of PSRs in 
the emerging markets of Asia Pacific (+3.7%) and Latin America (+0.3%), and their declining numbers in 
the established markets of North America (-0.9%), top 5 in Europe (-2.7%), other European countries (-
2.7%) and Japan (0.9%) from 2014 to 20151. These trends suggest that Africa is likely to be a region of 
intensified activities in the future, in particular its largest and likely most profitable markets such as 
Nigeria.  
 
Currently, there is limited information available on the nature of the encounters with PSRs and their 
impact on prescribing in Africa despite publications showing an impact 18,32-40. In Nigeria, only a few 
published studies have evaluated the interactions between Nigerian medical doctors and PSRs39,40. 
+RZHYHUWKHVHVWXGLHVGLGQRWDGGUHVVLVVXHVUHODWLQJWRSK\VLFLDQV¶DWWLWXGHWRZDUGV365VDQGtypically 
covered only one geopolitical region.  
 
Consequently, the objectives of this study were to explore the nature of current encounters between 
Nigerian physicians and PSRs, the types of medicines promoted and the extent to which these 
encounters influenced subsequent prescribing patterns. Subsequently, use these findings to provide 
guidance to Nigerian authorities and other relevant stakeholders on possible next steps to improve 
prescribing practices. This needs to be addressed to enhance the appropriate use of medicines and 
reduce out-of-pocket payments for patients in Nigeria. This is particularly important as Nigeria strives 
towards universal healthcare.  Further, the findings and suggestions of this study can potentially guide 
other LMICs striving to control the influence of pharmaceutical promotion activities on their physician 
prescribing habits. 
 
2. METHODOLOGY 
 
2.1 Study design 
This was a cross-sectional survey conducted among practicing physicians in tertiary health facilities in 
Nigeria. 
 
2.2 Study Site(s) 
Convenience sampling was used to select six tertiary health care facilities located in four out of the six 
geo-political zones of Nigeria: South-west, South-east, North-central and North-west. The rationale for 
selecting these facilities was the availability of personnel to carry out the study. We chose tertiary health 
care facilities for this study as they are the main training centres for physicians in Nigeria. As such, they 
play a very important role in establishing the prescribing habits of doctors and are therefore important 
targets for promotional activities by pharmaceutical companies.  
 
2.3 Study Instrument 
We developed 17-item structured questionnaire based on the literature on pharmaceutical 
promotion3,16,25,26 . The questionnaire consisted of three parts. The first part collected information on the 
socio-demographic characteristics of the respondents, the second on drug promotional activities, and the 
WKLUGRQWKHHIIHFWRISURPRWLRQDODFWLYLWLHVRQGRFWRUV¶SUHVFULELQJSUDFWLFHV$SSHQGL[$7KHVXUYH\ZDV
piloted among 10 physicians working in the general outpatient department of a tertiary healthcare facility 
in Lagos, Nigeria. Necessary amendments were then made based on responses received to enhance the 
clarity and the robustness of the subsequent findings. 
 
2.4 Sampling 
2.4.1 Sample size calculation 
The sampling frame consisted of an estimated 1110 physicians working in the six selected tertiary health 
care facilities located in four geo-political zones of Nigeria. Using the Raosoft® software41, we calculated 
a sample size of 167 participants under the assumption of a 50% response rate, at 7% margin error and 
95% confidence interval. Assuming a non-response rate of 5% from the piloted study, we obtained a final 
corrected minimum sample size of 175. However, a larger sample size of 250 physicians was used to 
allow adequate power of the study. 
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2.4.2 Participant Selection 
Physicians working in the selected tertiary health care facilities were chosen through stratified random 
sampling. The number of questionnaires sent to each of the participating tertiary health care facilities was 
proportional to their physician population. With each hospital, questionnaires were distributed between 
different departments based on the number of physicians working in each department.  
 
The names of all physicians (including medical interns) working in the clinical departments of selected 
hospitals were compiled from departmental staff lists and participants chosen using a random number 
interval. The selected physicians were approached during regular departmental meetings in each hospital 
and invited to participate in the study.  
 
2.4.3 Data collection 
The questionnaire was then administered by designated doctors in each of the participating centres for a 
period of approximately 30 minutes to those who agreed to take part in the study. Information was 
collected on promotional encounters between doctors and PSRs in the three months prior the survey. 
Data collection took place during the first two weeks of February 2016. There was no financial reward for 
taking part in the study. 
 
2.5 Ethical consideration 
The questionnaires were completed anonymously to ensure confidentiality. The acceptance of the 
doctors to complete the questionnaire was taken as explicit consent. A waiver for ethical approval was 
given as the study did not involve patients and sought only information about habits/clinical practice.  
 
2.6 Statistical Analysis 
The information obtained from the questionnaire was coded, entered and analyzed using IBM SPSS 
version 19. Univariate and multivariate analyses were conducted to test for the association between 
prescription of promoted medicines and the following variables: drug information provided during the 
promotional encounter, cost and efficacy of the drug, personality of the PSR, quality of the drug 
presentation and demographics of the participants. Pearson Chi-VTXDUHRU)LVKHU¶VH[DFWWHVWDQGWKH
Mann-Whitney test were used in the univariate analysis and binary logistic regression was used for the 
multivariate analysis. A p- value of <0.05 was considered significant.  
 
3. RESULTS 
 
3.1 Descriptive analysis 
Of the 250 questionnaires distributed to participants, 210 were returned, giving a response rate of 84%. 
However, 34 of which were incomplete and consequently were excluded. A total of 176 duly filled 
questionnaires were subsequently analysed for this study. The highest proportion of respondents were 
male doctors (80.7%), residents (50%%) and internal medicine residents (35.8%) (Table 1).  
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Table 1: Distribution of the respondents according to their demographic and professional characteristics 
 
Parameters  Median N (%) 
General characteristics 
Age(yrs) 
Years of practice 
Gender 
Male                                                                           
Female   
 
32 yrs 
4.0 yrs 
 
 
 
142 (80.7) 
34 (19.3) 
3K\VLFLDQ¶VFDGUHLQKLHUDUFKLFDORUGHU   
Interns (House Officers)  61 (34.7) 
Medical Officers  16 (9.1) 
Residents  88 (50) 
Consultants  11 (6.2) 
 
Specialty 
  
Internal Medicine  63 (35.8) 
Family Medicine/General Practice  43 (24.5) 
Obstetrics and Gynaecology  25 (14.2) 
Surgery  22 (12.5) 
Paediatrics  12 (6.8) 
Others  11 (6.2) 
 
The median age of the respondents was 32 years, with a mean age of 32.5±6.9 years. The median 
number of years of practice was 4 (IQR ± 1-5). Overall, 68% of the physicians had been practicing for five 
years or less, 21% had been practicing between six and ten years and 11% had been practicing for more 
than ten years. 
 
One hundred and fifty-four respondents (87.5%) had medicines promoted to them in the previous three 
months. In the majority of cases (86.4%), this happened over the course of one to five encounters with 
365V2XWSDWLHQWV¶FOLQLFVFOLQLFDOPHHWLQJVGUXJODXQFKHVPHGLFDOFRQIHUences 
(11.9%) and other organized events (8.5%) were the main points of drug promotion. The most commonly 
promoted medicines where indicated were anti-hypertensives (n=21), antimicrobials (n=14), multivitamins 
(n=12) and anti-lipidemic medicines (n=7) (Figure 1). 
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Figure 1: Groups of promoted medicines 
 
 
 
 
The information provided during the promotional encounters included the generic name of medicines 
(n=137, 77.8%), brand names (n=140, 79.5%), clinical indications (n=142, 80.7%), contra-indications 
(n=96, 54.5%), the pharmacological effects of drugs (n=114, 64.8%) and dosing information (n=124, 
70.5%). Information about potential adverse effects, drug interactions and storage conditions was 
provided in 73(41.5%), 48(27.3%) and 18(10.2%) of the cases, respectively. The majority of the 
respondents (68.2%) had received some gifts or incentives during their encounters with PSRs. Food, in 
the form of lunch or dinner, was the most common incentive offered (n=124, 70.5%), followed by gift 
items such as ward coats, pen and calendars with the names of the medicine/company branded on them 
(n=121, 68.8%), cash (n=7, 4%), conference sponsorship (n=6, 3.4%) and free drug samples (n=4, 
2.3%). 
 
Over half of the respondents (60.8%) felt motivated to prescribe the promoted medicines. The factors that 
may influence this included the perceived quality of information provided (63.6%), cost and efficacy of the 
presented medicine (51.1%), the reputation of the pharmaceutical company (28.4%), the quality of the 
presentation (18.2%), the personality of the PSR (9.1%) and the nature of the gifts/incentives (4.5%). 
Thirty-five percent of the physicians who were motivated to prescribe the promoted medicines would do 
so using the brand names, while 55.1% would use both brand and generic (INN ± International non-
proprietary name) names.   
 
More than half of the respondents (53.4%) would consult additional sources of information before 
considering to prescribe the promoted medicines. The sources of medicine information included the 
internet (39.2%), formularies such as the British National Formulary (BNF) and the Monthly Index of 
Medical Specialities (MIMS, a commercial prescribing guide), (30.1%), (Figure 2). Other factors 
influencing prescribing habits included their residual knowledge of pharmacology from medical school 
(79.5%), knowledge obtained during the medical internship (79.5%), influence of more senior colleagues 
(57.4%), availability of such medicines at the hospital pharmacy or nearby pharmacies (75%), whether 
WKHPHGLFLQHZRXOGEHDIIRUGDEOHIRUWKHSDWLHQWDQGSDWLHQWV¶UHTXHVWV)LQDOO\DQG
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50.2% of interns and residents mentioned that their prescribing choices were influenced by the opinion of 
senior colleagues. 
 
Figure 2: Alternative sources of information for prescribing 
 
 
 
Most doctors (n=114, 64.8%) agreed that the relationship between doctors and pharmaceutical medical 
representatives should be regulated. The Nigerian Medical Association (NMA), the Pharmaceutical 
Society of Nigeria (PSN) and NAFDAC were the identified organizations that could regulate this 
relationship. The forms of control suggested were outright prohibition of gifts and incentives from the 
pharmaceutical representatives (n=36, 20.5%), allowing physicians to receive only low-priced gift items 
(n=47, 28.7%), declaration of monetary/expensive gifts and stoppage of industry sponsored 
conferences/CME (n=2, 1.1%). 
 
In the univariate analysis (Table 2), more years of medical practice, the perceived quality of the 
information provided, the cost and efficacy of the medicine, the personality of the PSR, the receipt of gifts 
and expected rewards from the pharmaceutical company were significantly correlated with motivation to 
prescribe the promoted medicines.  
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Table 2: Demographics, cadre, and promotional drug variables compared for participants that are 
motivated or not motivated to prescribed promotional drugs   
 
Characteristics Motivated            
(n= 109) 
Not motivated        
(n= 70) 
P value 
Frequency (%)* or median (IQR)** 
Demographics 
Median (IQR) age of the participants (years) 32 (28-34) 31 (28-34) 0.309 
Median (IQR) years of practice 4 (2-7) 2 (1-6) 0.030* 
Specialty    
Family medicine 12 5 0.127 
Obstetrics and gynecology 17 8  
Surgery 11 11  
Paediatrics 7 5  
General Practice 18 8  
Others 10 1  
Gender 
Male 86 56 0.897 
Female 21 13  
Cadre/ Level 
Interns 29 32 0.051 
Medical officers 11 5  
Residents 61 27  
Consultants 6 5  
Promotional drug variables 
Adequate information provided during promotion 112 64 0.000 
Reputation of the drug marketing company 50 126 0.055 
Quality of the presentation 32 144 0.026 
Cost-benefit ratio of the drug 90 86 0.000 
Personality of presenter 16 160 0.022 
Gifts                     8                  168    0.020 
Future benefits from company                    6                  170    0.045 
 
Table 3 shows the results of the multivariate analysis of variables potentially associated with motivation to 
prescribe promotional medicines. The odds of the motivation to prescribe the promoted medicines were 
significantly lower with the reputation of the pharmaceutical company (adjusted odds ratio: 0.24, 95% CI: 
0.08- 0.74) but higher with the quality of presentation (adjusted odds ratio: 27.09, 95% CI: 8.43-87.11) 
and the cost-benefit ratio (10.90, 95% CI: 8.43- 28.48) of the promoted medicines.  
 
Table 3: Multivariate analysis of predictors that motivated the participants to prescribe promoted drugs  
 
Variable OR (95% CI) 
Unadjusted $GMXVWHGŋ 
Adequate information provided during 
promotion 
0.55 (0.15 ± 2.44) 0.61 (0.19 ± 2.04) 
Reputation of the pharmceutical company 0.20 (0.07- 0.65) 0.24 (0.08- 0.74) 
Quality of the presentation 29.16 (9.32 ± 88.21) 27.09 (8.43 ± 87.11) 
Cost-benefit ratio of the drug 12.80 (6.10 -30.36) 10.90 (4.18 -28.48) 
Personality of the pharmaceutical sales 
representative 
5.35 (0.76 -22.35) 3.37 (0.56 -20.28) 
Age of the physicians 1.02 (0.82- 1.09) 1.02 (0.91- 1.14) 
Specialty of the physician 0.70 (0.55- 1.00) 0.80 (0.64- 1.00) 
Year of practice 0.89 (0.78 ± 1.02) 0.95 (0.84 ± 1.08) 
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ŋ$GMXVWHGIRUFRYDULDWHVDJHVSHFLDOW\DQG\HDURISUDFWLFHRIWKHSK\VLFLDQDGHTXDWHLQIRUPDWLRQ
provided during promotion, reputation of the drug company, quality of the presentation, etc), OR= odds 
ratio, CI= confidence interval. 
 
4. DISCUSSION 
 
We were encouraged by the high response rate in our study (84%), which was appreciably higher than 
that seen by Pinto et al (25.5%)42. This study revealed that the majority (87.5%) of respondents had 
recent encounters with PSRs and received various forms of gifts/incentives from them. A study published 
LQRQPHGLFLQHV¶SURPRWLRQLQDWHDFKLQJKRVSLWDOLQ,ORULQ1LJHULDIRXQGWKDW9% of the doctors 
had encounters with PSRs in the preceding 6 months and more than two-thirds reported that their 
prescribing habits were affected by the promotional drug material received 18. This can be a concern if 
this leads to inappropriate prescribing especially if there is bias in the promotion materials16,21,22. 
However, as mentioned, Spurling et al found a variable association between exposure to pharmaceutical 
company information and lower quality prescribing, a higher frequency of prescribing and higher costs15, 
with Vancelik et al finding pharmaceutical companies were highly influential in the prescribing practices of 
ambulatory care physicians similar to Godman et al Akande et al816-17.  On the other hand, the importance 
of physician-PSR interactions as an efficient and convenient source of drug information has been noted in 
a number of studies26,32, and the adoption of structured educational programmes for young physicians 
and medical students on the interaction with PSRs can help improve their ability to maximise on the 
benefits of such interactions33,34,43.      
 
Among the medicines promoted to physicians were antihypertensives, antimicrobials and cholesterol-
lowering agents. The branded forms of these medicines can be expensive for individuals paying out-of-
pocket in a resource poor country, hence the need for generics. A concern is that almost a third of those 
motivated to prescribe the medicines being promoted would do so by brand name only. Studies have 
shown that prescribing by generic names could reduce the cost of medicines by as much as 90% or 
more, reducing overall medicine cost for the class as well as overall healthcare costs 44-47 . This is 
especially important for Nigeria where the majority of health care expenditure is still currently out-of-
pocket, with medicines being responsible for a substantial part of healthcare costs 48-50. This is being 
addressed in other African countries with pharmaceutical companies offering medicines for as little as 
1US$/patient/ month as part of improved access programmes51. There is now little controversy 
surrounding the prescribing of good quality generics with a number of meta analyses and other studies 
showing no difference in outcomes between generics and originators across a range of medicines and 
disease areas52-60, although recognizing there are some medicines which should not be prescribed by 
INN such as lithium and certain anti-epileptic medicines61-63, with generic immunosuppressants now less 
of an issue64. However, there are still concerns with the quality of generics in Nigeria, which needs to be 
addressed to enhance their use50. There are also concerns if interactions with PSRs increases empiric 
treatment with antibiotics enhancing potential antimicrobial resistance (AMR). Ethical drug promotion in 
developing countries has been identified as a means of containing AMR65.  
 
It can be argued that the majority of encounters between doctors and PSRs in our study were reasonable 
such as an offer of a lunch or dinner as an incentive for doctors to take time out of their schedules to 
listen to information provided about by pharmaceutical companies or offers gifts. While this may hold for 
doctors in high income countries, the case may differ for those in resource poor countries35,42,66-68.  A 
previous study in South East Nigeria indicated that 60% of the surveyed doctors felt influenced after 
receiving gratifications in the form stickers, food and souvenirs to prescribe promoted medicines40.  
 
Among the predictors to be motivated to prescribe promoted medicines, the odds of motivation were 
lower with greater years of practice. Similarly, the odds were lower when the pharmacological information 
of the medicine provided during the promotion activities were inadequate compared to when adequate 
information was provided. These findings are appropriate as they were expected since clinical and 
prescribing experiences are known to improve with years of practice of a doctor. Previous studies 
evaluating prescribing patterns of doctors in Nigeria have shown that junior doctors perpetrate the most 
prescribing errors and inappropriate prescribing69. Adequate pharmacological information of promoted 
medicine is essential for rational and appropriate prescribing70,71. By contrast, the odds of the motivation 
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to prescribe the promoted medicines were higher when the quality of the presentation was good 
compared to a poor quality presentation. Similarly, the odds of motivation were higher with a high cost-
benefit ratio of the promoted medicine compared to those medicines with a low cost-benefit ratio. Rational 
and appropriate prescribing entails cost-benefit considerations, which is particularly important in LMICs 
where the cost of medication is typically borne by the patient72.    
 
In this study, two thirds of respondents felt there should be some form of regulation between doctors and 
pharmaceutical companies and it was felt that this should be provided by the NMA in conjunction with the 
PSN and the NAFDAC.  Regulatory measures suggested by the respondents was either stopping the 
PSRs from offering gifts or offering only gifts with a low monetary value. In an international cross-sectional 
survey on educational initiatives for medical and pharmacy students about drug promotion, the majority of 
the respondents admitted that many countries do not have a functioning drug regulatory agency or other 
national private or public sector organizations responsible for overseeing drug promotion43. This may 
have informed the suggestion of most respondents in the current survey that drug promotion should be 
regulated by the two major associations for healthcare providers and NAFDAC, which is in keeping with 
the findings in high income countries42,73. The American Medical Association42 and the FDA73 are known 
to have played prominent roles in containing greater interactions between doctors and pharmaceutical 
companies in the US. 
 
Following increasing concern among health authorities and civil society in other countries, national 
legislations regulating the advertising and promotion of medicines have been developed in many 
developed countries with the United Kingdom and Australia as example67,68 . The pharmaceutical industry 
themselves have also developed voluntary codes of conduct to address concerns, outlining ethical 
principles that should guide the promotion of medicines, and the interactions between pharmaceutical 
companies and the health care community, across countries29 . For example, these principles and rules 
outline the kind of interactions PSRs can have with health care professionals and what claims can be 
made about the prescription medicines being promoted, as well as other areas of interaction with the 
health care community such as clinicals trials and interactions with patient representatives28 .  
 
There are a number of examples of such codes including the 2012 International Federation of 
Pharmaceutical Manufacturers and Associations (IFPMA) Code of Practice, the 2009 Code on 
Interactions with Healthcare Professionals of the Pharmaceutical Research and Manufacturers of 
America (PhRMA) and the 2014 Code of Conduct of the European Association of Researching 
Pharmaceutical Industries (EFPIA)74-76 . Such industry self-regulatory codes have also been developed in 
emerging economies such as India, China and South Africa77-79. However, evidence from Sweden and the 
United Kingdom shows that industry self-regulation does not always work 80. This is due to four main 
inherent challenges. Firstly, self-regulation by pharmaceutical companies can be perceived as a conflict 
of interest as the codes are developed and implemented by the party with financial motivations; secondly, 
they are voluntary. Thirdly, due to general lack of pre-vetting and reactive monitoring, breaches are 
typically brought to light, and sanctions only administered, once the campaigns have already affected 
health professionals and consumers. Fourthly, financial penalties can be too low to be really effective81. 
 
In Nigeria, while there is some regulation for the advertising of pharmaceutical products by NAFDAC30, 
there is currently no regulation by the Government on pharmaceutical company promotion and there is no 
body monitoring unethical promotional practices. Consequently, this research highlights a need for the 
Nigerian government to develop a code of conduct that will address some of the raised concerns. In view 
of our findings, we recommend the development of a legal provision on all pharmaceutical promotion, 
which is currently missing as the existing legislation only covers the advertising of medicinal products. 
There could for instance be financial and other consequences for pharmaceutical companies that violate 
the laws, if and when established, similar to other countries82, 83. However, getting the necessary 
manpower to enforce any developed code of conduct as well as obtaining the resources to address 
identified problems are potential challenges in resource limited countries such as Nigeria.  
 
Limited information was also given to physicians regarding adverse drug affects, potential drug-drug 
interactions and storage conditions of promoted medicines, by PSRs during their interactions with 
physicians, which is similar to other countries20. This has been a consistent problem, and is a short-
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sighted approach, as the lack of key information could potentially lead to serious adverse reactions for 
patients or even withdrawals if vital information is not disclosed84,85 .  
 
On the implementation side, drug and therapeutic committees (DTCs) should be key players in hospitals 
in the training of physicians in the appropriate use of medicines along with clinical pharmacologists and 
clinical pharmacists. We are already seeing such activities grow across Europe to enhance appropriate 
use of medicines in hospitals given increasing pressures for funding new medicines70,71,86,87, providing 
examples to Nigeria. There are also ongoing programmes among public hospitals in South Africa to 
improve the functioning of DTCs and the reporting of adverse drug reaction in hospitals to enhance the 
appropriate use of medicines as well as reduce the need and influence of PSRs88-91 .  
 
There are various reports that regulation of interaction between medical students, interns, residents and 
PSRs influences their future relationship and practice92,93. In the nearest future, medical students, interns, 
and residents who have interacted with PSRs are not willing to further interact with the industry once they 
started to practice43,92,93. This underscores the importance of education of physician in training on how to 
critically evaluate the adequacy of pharmacological information of promoted drugs before prescribing. 
Such educational training has been recognized by the WHO and Health Action International (HAI) and 
contained in a practical guide handbook on understanding and responding to pharmaceutical promotion43.  
 
Consequently, the next stage of our research will be to document further current DTC activities in Nigeria 
and the implications, building on the recent findings from a pilot study94. Furthermore, we will start 
promoting the fact that the university curricula of medical doctors, nurses, and pharmacists in Nigeria 
should now include education about pharmaceutical promotion, the need for regulations and the existing 
regulatory framework in the country, alongside general education about the appropriate use of medicines.  
 
Efforts should also be geared towards encouraging all professionals in Nigeria to use the WHO and HAI 
practical handbook to guide their understanding and response to pharmaceutical promotion43. 
Educational activities continue as part of continuous professional development once physicians are 
qualified along with activities to potentially strengthen DTCs in hospitals as learning organisations. Finally, 
independent information on efficacy and safety of medicines should be made available to health 
professionals and patients. In countries with developing health care systems, limited availability of this 
information is often the reason for physicians to rely on promotional material19 to the detriment of patients 
and the healthcare system.  
 
4.1 STUDY LIMITATIONS 
This study was conducted among physicians working in tertiary health care facilities in Nigeria, almost all 
of which are located in urban centres and managed by the government. As such, our findings may not be 
applicable to physicians working in other care settings (e.g. private and faith-based health facilities). The 
majority of the respondents were also young (< 40 years) with limited years of practice (average of 4 
years) suggesting they were junior doctors. This may not represent the majority of doctors in Nigeria as 
 only a limited number of consultants participated in the survey. Previous questionnaire-based studies 
involving doctors in Nigeria though have also shown that consultants very rarely participate in such 
surveys95,96. It is to be hoped that future studies would address this problem. Nonetheless, we believe our 
data is representative of doctors in Nigeria since the population of residents and interns at any point in a 
year is far more than those of the consultants in all teaching hospitals in Nigeria. In addition, given the 
sensitivity of the topic, some respondents may not have been fully honest in their responses. 
 
However, we believe these limitations are offset by the multi-centered nature of the study, the focus on 
teaching hospitals where future physicians are trained and the anonymity of completed questionnaires. 
As a result, we believe our findings provide important insights regarding the current extent and impact of 
pharmaceutical promotion among teaching hospitals in Nigeria. Such findings can be used to inform 
interventions and policy changes aimed at improving pharmaceutical promotion practices in line with 
international best practices to enhance the quality of future prescribing. Future studies will be conducted 
among a larger selection of hospitals in Nigeria with opportunities for interventions, and post-intervention 
analyses, based on recommended changes.  
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5. CONCLUSION 
 
Our findings on the impact of pharmaceutical promotion in Nigeria on prescribing habits are a concern as 
this may negatively impact on the quality of prescribing and the cost of treating both communicable and 
non-communicable diseases in Nigeria. Enhancing the quality and efficiency of prescribing is key to 
improving patient outcomes, reducing out-of-pocket expenditure on medicines for patients, and reducing 
expenditure for health care systems. Greater efforts, not just in regulating, but most importantly in 
ensuring that regulations are implemented, are needed. Rigorous studies on the impact of pharmaceutical 
promotion can make an evidence-based case for this need. Strengthening the implementation of 
regulations of pharmaceutical promotion requires monitoring and evaluation of regulatory effectiveness in 
Nigeria. This will help in reducing inefficiencies in prescribing and the use of medicines, especially as 
African countries are striving for universal access. Practical steps towards reducing the impact of drug 
promotion on inappropriate physician prescribing in Nigeria would include enforcement of generic 
prescribing in healthcare facilities providing their quality can be assured as well as the establishment of 
functioning DTCs to guide future medicine use including the uptake of new medicines into the healthcare 
system. 
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APPENDIX A 
 
SURVEY OF IMPACTS OF DRUG PROMOTIONAL ACTIVITIES ON THE PRESCRIBING PATTERNS 
AND PRACTICES OF DOCTORS IN SOME SELECTED TERTIARY HEALTH FACILITIES 
 
Introduction: 
Dear Sir/Madam, 
This study is being carried out among doctors in tertiary health institutions in some Nigerian cities to gain 
insight into the impact of drug promotional activities on their practices. The purpose of this study is not to 
indict you or any organization. It is a self- sponsored research for academic purposes only. Your honest 
response is therefore important and will be greatly appreciated. You are to respond on the basis of 
anonymity and your responses will be given the utmost confidentiality required. Thank you. 
6(5,$/180%(5«««««««««««« 
SECTION A (DEMOGRAPHY AND PROFESSION) 
Age last birthday ----------------------------------- 
 
Sex , Male = 1, Female = 2   
 
Number of year/s of Practice -------------------- 
 
Professional status 
House officer = 1, Medical officer=2, Senior medical officer and above=3, Registrar=4, Senior 
Registrar=5, Consultant =6. 
Area of Practice 
      General Practice = 1, Family Medicine=2, Internal Medicine = 3, Surgery = 4, 
      Pediatrics = 5, Obstetrics & Gynecology = 6, Psychiatry = 7, Ophthalmology = 8, Ear Nose andThroat 
(ENT) = 9, Dentistry =10, 
      2WKHUV SOVVSHFLI\««««««« 
SECTION B (DRUG PROMOTIONAL ACTIVITIES) 
How many times have you had drug/s promoted WR\RXLQWKHODVWPRQWKV«««««««« 
 
In which of the settings below did such activities/interactions take place? 
 
 Settings Mark X Frequency in 
last 3 months 
a Outpatient clinic visit   
b Statutory Clinical meetings    
c Organized outdoor events   
d Drug launch   
e Conferences   
f 2WKHUVSOHDVHVVSHFLI\«««   
Multiple responses allowed.  
 
Can you please list the names of drugs promoted to you in the last 3 months 
«««««««««««««««««««««««««««««««««««««««««««« 
«««««««««««««««««««««««««««««««««««««««««««« 
«««««««««««««««««««««««««««««««««««««««««««« 
  
Please indicate the information provided during the promotional events you have had? 
 
 Information Yes No 
a Generic name of the drug   
b Brand name of the drug   
c Clinical indications   
d Contraindications/Cautions   
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e Pharmacological effects of the drug   
f Mode of action   
g Pharmacokinetics   
h Dosing information   
i Potential adverse effects   
j Average duration of treatment recommended   
k Potential drug interactions   
l Available dosage forms   
m Product and package descriptions   
n Route of administrations   
o Drug additives used   
p Storage conditions   
q Expiration dates/shelf life   
r Name/Address of manufacturers   
s Alternate sources of information about the drug    
t Drug local registration information/NAFDAC no   
u Name/address of the drug marketer   
v Reference materials/ Relevant Publications   
w Cost of the drug   
x 2WKHUVSOVVSHFLI\««««««««««   
 
Were gifts or incentives distributed at such fora 
Yes = 1, No =2 
 
Kindly indicate the type/s of gifts/incentives you have once received from a pharmaceutical organisation 
 
 Items Mark X 
a Food items (launch/dinner/snacks/drinks)  
b Souvenirs (e.g. pen, writing pads, mug, keys 
holders, wallets, clock, organizers, ward coats) 
 
c Cash   
d Sponsorship to conferences  
e 2WKHUVSOVVSHFLI\««««««««  
 
SECTION C (PRESCRIBING HABITS) 
 
Have you in any way being motivated by the promotional activity/ies to prescribe a drug? 
Yes = 1, No = 2 
 
What contributed to your being motivated to prescribe such drug/s? 
 
 Factor/s Mark X 
a Information provided during the promotion 
encounter 
 
b Reputation of the organization  
c Personality of the pharmaceutical sales 
representative 
 
d The gifts/motivational items received  
e Perceived future benefits from the company  
f The quality of the presentation  
g The cost and efficacy of the product  
h Others, please specify 
««««««««««««« 
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If yes to 12 above, in what form is/are the drug/s prescribed? 
Generic name only = 1, Brand name only =2, Both brand and generic names = 3, Acronyms = 4  
 
Apart from the drug promotional forum/a, did you source for more information about such drugs before 
prescribing? 
Yes =1, No = 2. 
 
If yes to 15 above, what was/were the source/s of such additional information sort? 
 
 Source Mark X 
a Print materials received at presentation  
b Drug formulary/ies (e.g. BNF, MIMS)  
c Posters and bill boards  
d Peer reviewed journals  
e Print medias  
f Electronic medias  
g Pharmacology textbooks  
h Colleagues  
i Internet resources  
j Other, please specify 
«««««««««««« 
 
 
Other than drug promotional activities, which of the following factors has influenced your prescribing 
practices? 
 
 Factors Yes No 
a Knowledge acquired from medical school   
b Knowledge acquired during internship   
c Knowledge acquired during postgraduate 
training 
  
d Senior colleagues influences and preferences   
e Drug availability   
f Common practice in medical community   
g Personal experience with the drug   
h Affordability to patients   
i 3DWLHQW¶VSULRULW\   
j Out of curiosity   
k 2WKHUVSOVVSHFLI\««««««««««««   
 
Do you agree that the relationship between doctors and pharmaceutical medical representatives should 
be regulated?  Yes =1, No = 2. 
 
If yes, in what form should the regulation be 
 Regulation  
A Stopping all kinds of gifts                
B Allowing only souvenirs/gift with small monetary value  
C Declaration of monetary value of expensive gifts/ 
sponsorships 
 
D Stopping industry sponsorship of conferences/CME  
E 2WKHUV«  
 
Thank you. 
 
 
 
